Thanks for pointing out the NPR link was 5.5 months old. In haste to post I mixed that big initial wave with the current. I am unable to alter the post. Here is a more current article. (from May 26 2023) You will notice that the dates have changed but Covid is still very much present in China. Such as it is with Covid, you have a peak which is then followed by waves.
As in the earlier link it's still serious in China it appears; "BEIJING — China is bracing for a new wave of Covid infections that could see as many as 65 million cases per week by the time the surge peaks at the end of June."
As it pertains to the link I posted, the newer link somewhat addresses the results of that wave;
"During China’s first omicron wave in December and January, a different omicron variant was infecting millions of people every day, overwhelming hospitals and crematoriums in cities across the country. Store shelves were emptied of fever medications and schools were shut down.
About 80% of China’s 1.4 billion people were infected during that wave, Wu Zunyou, chief epidemiologist at the Chinese Center for Disease Control and Prevention, said in January. But immunity may have waned in the months since, raising the risk of reinfection."
I appreciate the feedback for the sake of accuracy. ======
I remain skeptical that covid is over. I remain in the opinion that more covid registration trials can still happen. The fact that Pfizer is attempting an improved antiviral to replace Paxlovid is ample proof of that- not only that there is a future market, that there is a path forward to getting an improved drug approved, or that a drug can be shown to be non- inferior to Paxlovid. I've mentioned months before that the bar to approval is very low, which I think you may agree since you seem to have a low opinion of Paxlovid's efficacy.
And in that you seem to feel that the next gen Pfizer drug has great potential I infer you must also agree. What I cannot grasp is how in your mindset that approval is possible for competitors, but also somehow impossible for Enanta's EDP 235.
News 
Market Data 
Discover 
